- Home
- SAFE vs DVAX Comparison
SAFE vs DVAX Comparison
Compare SAFE & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAFE
- DVAX
- Stock Information
- Founded
- SAFE 2016
- DVAX 1996
- Country
- SAFE United States
- DVAX United States
- Employees
- SAFE N/A
- DVAX N/A
- Industry
- SAFE Real Estate Investment Trusts
- DVAX Biotechnology: Pharmaceutical Preparations
- Sector
- SAFE Real Estate
- DVAX Health Care
- Exchange
- SAFE Nasdaq
- DVAX Nasdaq
- Market Cap
- SAFE 1.2B
- DVAX 1.2B
- IPO Year
- SAFE 2017
- DVAX 2004
- Fundamental
- Price
- SAFE $14.78
- DVAX $10.03
- Analyst Decision
- SAFE Buy
- DVAX Buy
- Analyst Count
- SAFE 8
- DVAX 4
- Target Price
- SAFE $19.88
- DVAX $26.50
- AVG Volume (30 Days)
- SAFE 359.4K
- DVAX 1.7M
- Earning Date
- SAFE 10-27-2025
- DVAX 11-06-2025
- Dividend Yield
- SAFE 4.79%
- DVAX N/A
- EPS Growth
- SAFE N/A
- DVAX N/A
- EPS
- SAFE 1.43
- DVAX N/A
- Revenue
- SAFE $393,596,000.00
- DVAX $316,268,000.00
- Revenue This Year
- SAFE $0.77
- DVAX $23.23
- Revenue Next Year
- SAFE $5.19
- DVAX $16.57
- P/E Ratio
- SAFE $10.33
- DVAX N/A
- Revenue Growth
- SAFE 2.22
- DVAX 26.66
- 52 Week Low
- SAFE $13.43
- DVAX $9.20
- 52 Week High
- SAFE $25.36
- DVAX $14.63
- Technical
- Relative Strength Index (RSI)
- SAFE 36.39
- DVAX 48.58
- Support Level
- SAFE $15.30
- DVAX $9.95
- Resistance Level
- SAFE $15.46
- DVAX $10.36
- Average True Range (ATR)
- SAFE 0.38
- DVAX 0.29
- MACD
- SAFE -0.12
- DVAX 0.06
- Stochastic Oscillator
- SAFE 1.24
- DVAX 59.64
About SAFE Safehold Inc. New
Safehold Inc is a REIT that operates its business by acquiring, managing, and capitalizing ground leases. Ground leases are long-term contracts between the landlord (the Company) and a tenant or leaseholder. Ground leases generally represent ownership of the land underlying commercial real estate projects that are net leased by the fee owner of the land to the owners/operators of the real estate projects built thereon.
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.